BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 26454859)

  • 1. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
    Neagu MR; Reardon DA
    Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
    Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
    Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time trends in glioblastoma multiforme survival: the role of temozolomide.
    Dubrow R; Darefsky AS; Jacobs DI; Park LS; Rose MG; Laurans MS; King JT
    Neuro Oncol; 2013 Dec; 15(12):1750-61. PubMed ID: 24046259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
    Pan E; Mitchell SB; Tsai JS
    J Neurooncol; 2008 Jul; 88(3):353-7. PubMed ID: 18389176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
    Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
    J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
    Carter TC; Medina-Flores R; Lawler BE
    Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
    Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B
    Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
    Shields LB; Kadner R; Vitaz TW; Spalding AC
    Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
    McNamara MG; Lwin Z; Jiang H; Chung C; Millar BA; Sahgal A; Laperriere N; Mason WP
    J Neurooncol; 2014 Mar; 117(1):153-60. PubMed ID: 24469855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.
    Ardon H; Van Gool S; Lopes IS; Maes W; Sciot R; Wilms G; Demaerel P; Bijttebier P; Claes L; Goffin J; Van Calenbergh F; De Vleeschouwer S
    J Neurooncol; 2010 Sep; 99(2):261-72. PubMed ID: 20146084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
    Sakamoto N; Ishikawa E; Yamamoto T; Satomi K; Nakai K; Sato M; Enomoto T; Morishita Y; Takano S; Ohno T; Tsuboi K; Matsumura A
    Neurol Med Chir (Tokyo); 2011; 51(4):319-25. PubMed ID: 21515959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.
    Michaelsen SR; Christensen IJ; Grunnet K; Stockhausen MT; Broholm H; Kosteljanetz M; Poulsen HS
    BMC Cancer; 2013 Sep; 13():402. PubMed ID: 24004722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
    Yahyanejad S; King H; Iglesias VS; Granton PV; Barbeau LM; van Hoof SJ; Groot AJ; Habets R; Prickaerts J; Chalmers AJ; Eekers DB; Theys J; Short SC; Verhaegen F; Vooijs M
    Oncotarget; 2016 Jul; 7(27):41251-41264. PubMed ID: 27183910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.